| T. Rowe Price Health Sciences Port |
|
 |
|
| Release date as of 2024-03-31. Data on page is subject to change. |
|
|
| Fees and Expenses |
Taken from prospectus dated 2023-05-01 |
|
| Maximum Fees |
| Administrative |
--- |
| Management |
0.95%
|
| 12b-1 |
--- |
|
|
| Actual Fees |
| 12b-1 |
--- |
| Management |
0.95%
|
| Expense Ratio |
0.94%
|
(taken from annual report dated 2023-12-31) |
| Total Annual Operating Expense |
0.95%
|
|
|
|
|
Type |
Date |
% |
| ManagementFee |
Contractual |
2024-04-30 |
0.01 |
|
|
|
|
|
| Inception Date: 2000-12-29 |
|
|
|
|
| Mngr Name |
Ziad Bakri |
| Mngr Start Date |
2016-04-01 |
|
| Biography |
| Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban |
|
|
|
| T. Rowe Price Associates, Inc. |
|
|
© Copyright 2024 Morningstar, Inc. All rights reserved. Morningstar, the Morningstar logo, Morningstar.com, Morningstar Tools are either trademark or service marks of Morningstar, Inc. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or any losses arising from any use of information. Past performance is no guarantee of future performance. |
|
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.
|
|
